Leptin, a hormone historically recognized for regulating appetite and energy homeostasis, is increasingly appreciated as a central mediator of immune function, metabolic integration, and tissue-specific signaling. Despite decades of research, leptin resistance limits the efficacy of conventional therapies, such as hormone replacement, in treating obesity and related disorders. Emerging evidence demonstrates that leptin interacts bidirectionally with the gut microbiome, influencing systemic metabolism and immune responses. Advances in multi-omics profiling, synthetic biology, and tissue-targeted therapeutics provide unprecedented opportunities to overcome these barriers. Here, we present a perspective emphasizing integrative strategies that combine precision medicine, immune modulation, engineered leptin analogs, and microbiome-targeted interventions. Leveraging these innovations could redefine leptin-based therapies, enabling system-level restoration of metabolic and immune homeostasis. Understanding leptin as a pleiotropic, multi-system hormone positions it at the forefront of the next endocrine paradigm.
Junaid et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: